Skip to main content
SpringerLink
Log in

Fda Perspective on Study Design for Therapies for Severe Sepsis

  • Published:
Sepsis

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  1. Dellinger RP, Opal SM, Rotrosen D, et al. Proceedings of a Conference on the Future of Sepsis Research. Chicago, IL: American College of Chest Physicians, 1997.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Food and Drug Administration, Maryland

    William Schwieterman & Rosemary Roberts

Authors
  1. William Schwieterman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rosemary Roberts
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schwieterman, W., Roberts, R. Fda Perspective on Study Design for Therapies for Severe Sepsis. Sepsis 1, 69 (1997). https://doi.org/10.1023/A:1009775621047

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1009775621047

Keywords

Search

Navigation